Human Genome Sciences has set its oncology and immunology goals for 2011.The therapies at the center of these goals are in the mid and early stage pipelines.The firm's oncology portfolio is centered around its expertise in the programmed cell death approach.
Human Genome's monoclonal antibody mapatumumab is being studied in combination with Nexavar as a treatment for advanced hepatcellular cancer.At the same time,The company's HGS1029 is being evaluated as a treatment for solid and advanced lymphoid tumors.
HGS1029 is one of a new class of compounds that block IAP proteins from protecting cancer cells.HGS1029 will be studied both alone and in combination with other agents,such as mapatumumab.HGS will initiate and continue the clinical trials of these oncology therapies in 2011.
CEO Thomas H. Watkins announced these and other goals on January 10 at the 29th Annual JP Morgan Healthcare Conference in San Francisco.Human Genome Sciences is based in Rockville,Maryland and has more than a billion dollars of cash and investments in its war chest.That is considered a lot for a young biotech concern such as Human Genome.
Human Genome Sciences(HGSI)
No comments:
Post a Comment